Page 58 - 南京医科大学学报自然科学版

第43卷第12期
·1674 · 南 京 医 科 大 学 学 报 2023年12月

zumab for first⁃line treatment of metastatic nonsquamous ［22］ JOHNSON D B，BALKO J M，COMPTON M L，et al. Ful⁃
NSCLC［J］. N Engl J Med，2018，378（24）：2288-301 minant myocarditis with combination immune checkpoint
［11］ PAZ⁃ARES L，VICENTE D，TAFRESHI A，et al. A ran⁃ blockade［J］. N Engl J Med，2016，375（18）：1749-1755
domized，placebo⁃controlled trial of pembrolizumab plus ［23］RUBIO⁃INFANTE N，RAMÍREZ⁃FLORES Y A，CASTIL⁃
chemotherapy in patients with metastatic squamous LO E C，et al. A systematic review of the mechanisms in⁃
NSCLC：protocol⁃specified final analysis of KEYNOTE⁃ volved in immune checkpoint inhibitors cardiotoxicity
407［J］. J Thorac Oncol，2020，15：1657-1669 and challenges to improve clinical safety［J］. Front Cell
［12］ HARATANI K，HAYASHI H，CHIBA Y，et al. Associa⁃ Dev Biol，2022，10：851032
tion of immune⁃related adverse events with nivolumab effi⁃ ［24］ WANG R，SHI M，JI M，et al. Real world experience with
cacy in non ⁃ small ⁃ cell lung cancer［J］. JAMA Oncol， camrelizumab in patients with advanced non ⁃ small cell
2018，4（3）：374-378 lung cancer：a prospective multicenter cohort study（NO⁃
［13］ SOCINSKI M A，JOTTE R M，CAPPUZZO F，et al. Asso⁃ AH⁃LC⁃101）［J］. Transl Lung Cancer Res，2023，12（4）：
ciation of immune⁃related adverse events with efficacy of 786-796
atezolizumab in patients with non⁃small cell lung cancer： ［25］ YIN L，LIU K C，LV W F，et al. Predicting outcome in
pooled analyses of the phase 3 IMpower130，IMpower132， combination treatment of TACE and camrelizumab for ad⁃
and IMpower150 randomized clinical trials［J］. JAMA On⁃ vanced hepatocellular carcinoma：tumor hypervascularity
col，2023，9（4）：527-535 and reactive cutaneous capillary endothelial proliferation
［14］ 中国临床肿瘤学会指南工作委员. CSCO免疫检查点抑 ［J］. Drug Des Devel Ther，2022，16：3421-3429
制剂相关的毒性管理指南2023［M］. 北京：人民卫生出 ［26］ WANG F，QIN S，SUN X，et al. Reactive cutaneous capil⁃
版社，2023：1-192 lary endothelial proliferation in advanced hepatocellular
［15］ BRAHMER J R，LACCHETTI C，SCHNEIDER B J，et al. carcinoma patients treated with camrelizumab：data de⁃
National comprehensive cancer network. management of rived from a multicenter phase 2 trial［J］. J Hematol On⁃
immune⁃related adverse events in patients treated with im⁃ col，2020，13（1）：47
mune checkpoint inhibitor therapy：American society of ［27］ OKIYAMA N，TANAKA R. Immune ⁃ related adverse
clinical oncology clinical practice guideline［J］. J Clin events in various organs caused by immune checkpoint in⁃
Oncol，2018，36（17）：1714-1768 hibitors［J］. Allergol Int，2022，71（2）：169-178
［16］ THOMPSON J A. New NCCN guidelines：recognition and ［28］ MAYOUX M，ROLLER A，PULKO V，et al. Dendritic
management of immunotherapy⁃related toxicity［J］. J Natl cells dictate responses to PD⁃L1 blockade cancer immu⁃
Compr Canc Netw，2018，16（5S）：594-596 notherapy［J］. Sci Transl Med，2020，12（534）：7431
［17］ COUZIN ⁃ FRANKEL J. Breakthrough of the year 2013. ［29］ YEARLEY JH，GIBSON C，YU N，ET al. PD⁃L2 expres⁃
Cancer immunotherapy［J］. Science，2013，342（6165）： sion in human tumors：relevance to anti⁃PD⁃1 therapy in
1432-1433 cancer［J］. Clin Cancer Res，2017，23（12）：3158-3167
［18］ BAJWA R，CHEEMA A，KHAN T，et al. Adverse effects ［30］ KICHENADASSE G，MINERS J O，MANGONI A A，et
of immune checkpoint inhibitors（programmed death⁃1 in⁃ al. Multiorgan immune ⁃ related adverse events during
hibitors and cytotoxic T⁃lymphocyte⁃associated protein⁃4 treatment with atezolizumab［J］. J Natl Compr Canc Netw，
inhibitors）：results of a retrospective study［J］. J Clin 2020，18（9）：1191-1199
Med Res，2019，11（4）：225-236 ［31］ SHANKAR B，ZHANG J，NAQASH A R，et al. Multisys⁃
［19］ KUMAR P，SAINI S，PRABHAKAR B S. Cancer immuno⁃ tem immune ⁃ related adverse events associated with im⁃
therapy with check point inhibitor can cause autoimmune mune checkpoint inhibitors for treatment of non ⁃ small
adverse events due to loss of Treg homeostasis［J］. Semin cell lung cancer［J］. JAMA Oncol，2020，6（12）：1952-
Cancer Biol，2020，64：29-35 1956
［20］ TOPALIAN SL，HODI F S，BRAHMER J R，et al. Safety， ［32］ DAS S，JOHNSON D B. Immune⁃related adverse events
activity，and immune correlates of anti⁃PD⁃1 antibody in and anti⁃tumor efficacy of immune checkpoint inhibitors
cancer［J］. N Engl J Med，2012，366（26）：2443-2454 ［J］. J Immunother Cancer，2019，7（1）：306
［21］ VADDEPALLY R，DODDAMANI R，SODAVARAPU S， ［33］ RIEDER D，TRAJANOSKI Z. Checking immunotoxicity
et al. Review of immune⁃related adverse events（irAEs）in risks of checkpoint blockade［J］. Nat Cancer，2023，4
non ⁃ small ⁃ cell lung cancer（NSCLC）⁃ their incidence， （6）：779⁃780
management，multiorgan irAEs，and rechallenge［J］. Bio⁃ ［收稿日期］ 2023-07-26
medicines，2022，10（4）：790 （本文编辑：唐 震）